Clinical trial
A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis…
NCT00266227 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00266227 |
|---|---|
| Title | A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate |
| Acronym | SUNRISE |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | placebo, rituximab, methotrexate, folate |
| Enrollment | 559 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2007 |
| First posted | Dec 16, 2005 |
| Last update posted | Oct 25, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: